MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Category: HEALTHCARE & MEDICINE

Proportion
Tiash SahaJuly 19, 2018

Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients

Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.

Proportion
Tiash SahaJune 3, 2018

This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’

AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.

Proportion
Tiash SahaMay 28, 2018

15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)

Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.

Proportion
Tiash SahaMay 22, 2018

First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved

2016 founded company, Dova Pharma's first drug, Doptelet received US FDA approval as the first oral treatment option to reduce the risk of blood loss in patients with chronic liver disease.

Proportion
Tiash SahaMay 18, 2018

First Migraine-Preventing Drug ‘Aimovig’ Bags FDA Approval

Much conversation and research were going on over a couple of years on a new class of drug- CGRP inhibitors and its potential to prevent and treat a migraine. The US FDA has approved the first treatment- Aimovig (erenumab-aooe) to prevent migraine in adults, belonging to the new class of drug called CGRP inhibitors. Aimovig is developed by Amgen. Read the article to know about Aimovig and developments in the popular area of migraine research- CGRP inhibitors.

Proportion
Tiash SahaMay 10, 2018

IIT Roorkee’s Innovative Bone Implant Technology Could Tap Emerging Orthopedic Market

Indian Institute of Technology Roorkee (IIT Roorkee) scientists have developed an improved orthopedic implant technology for sustained drug release. Currently, the technology is with the company, Biotech Consortium India Limited (BCIL) for transfer, for the commercialization of the technology.

Proportion
Tiash SahaApril 26, 2018

First Drug to Treat Polycystic Kidney Disease Bags FDA Approval

First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.

Proportion
Tiash SahaApril 20, 2018

Drug Innovation: FDA Approves Seven New Drugs in Four Months (Jan-Apr 2018)

Within first four months of 2018, seven new drugs are already approved by the FDA for a wide range of diseases including HIV, psoriasis, and rare cancers. 2018 will also see the first ever “game-changing” CRISPR gene editing clinical trial in humans.

Proportion
Tiash SahaApril 13, 2018

First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production

Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.

Proportion
Tiash SahaApril 5, 2018

Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review

The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

  • 1
  • 2
  • 3
Privacy Policy Terms Payment Policy Education Contact Us About us